B+
Bull case
15%
Probability
Target price
$8.25
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
RGC
Regencell BioscienceDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The May financing could improve near-term liquidity, while a future credible clinical or regulatory milestone could materially improve the company’s early-stage valuation profile.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Cash was approximately $2.4 million as of December 31, 2025, before the later financing activity was fully confirmed in the packet.
Momentum
98
Value
49
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.90 · Bull $8.25 · Bear $3.50Analysis 2026-08-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Why
Momentum98 · Δ7d +94.5
Value49 · Δ7d 0.0
Sentiment30 · Δ7d -37.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Cash was approximately $2.4 million as of December 31, 2025, before the later financing activity was fully confirmed in the packet.
- • Legal and investigation-related costs may remain material; the company disclosed pending litigation and investigation-related uncertainty.
- • The company remains loss-making with limited cash relative to its market capitalization, elevated legal and professional costs, no evidenced dated clinical catalyst, and substantial potential equity-supply risk.
Catalyst clock
2026-05-08
Interim results showed a deeper loss and elevated legal costs
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendImproving
Δ7d
+94.5
Δ21d
+94.5
Value
49
47% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
30
45% active weight
Current posture
7d trendSoftening
Δ7d
-37.4
Δ21d
-37.4
Why this grade
Composite grade D. Momentum 97.6 / Value 49.3 / Sentiment 29.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-06. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.90
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$3.4B
Beta
2.02
Shares Out
495.88M
P/E (TTM) · Derived
-289.5
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+22.6%
Gross Margin
-
Op Margin
-
Net Debt
-$4.35M
Current Ratio
1.42
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data